Skip to main content
SpringerLink
Log in

Pseudomonas vaccine: A phase I evaluation for cancer research

  • Original Articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

A heptavalent lipopolysaccharide vaccine of Pseudomonas aeruginosa (Pseudogen) was administered at four dose levels (0.1, 0.25, 0.5, and 0.75 mg/m2) to patients with advanced metastatic cancer that had proved refractory to chemotherapy. The vaccine was administered subcutaneously twice weekly. Local toxicity was seen in erythema, edema, pain and tenderness at the site of injection, and painful regional lymphadenopathy; manifestations of systemic toxicity included fever, chills, myalgias, nausea, and vomiting. Toxicity showed a clear-cut dose dependence. The maximally tolerated dose by this route and schedule was 0.5 mg/m2. A significant rise of antibody titers was observed at all four dose levels. Evaluation of the delayed cutaneous hypersensitivity response to recall antigens and to the pseudomonas vaccine, and quantification of peripheral blood T and B cell levels and of in vitro lymphocyte blastogenic responses to commonly used mitogens and pseudomonas vaccine failed to demonstrate significant change from pretreatment values. Clinical trials to evaluate the therapeutic efficacy of pseudomonas vaccine with or without chemotherapy can be undertaken safely with this route and schedule.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adkins, E., Frances, L.: Role of lymphocytes in the pyrogenic response: comparison of endotoxin with specific antigen and the non-specific mitogen, Con-Conavalin-A. I. infect. Dis. 128 (Suppl.), S277-S283 (1973)

    Google Scholar 

  2. Alexander, J. W., Fischer, M. W.: Immunological control of Pseudomonas infection in burn patients: A clinical evaluation. Arch. Surg. 102, 31–35 (1971)

    Google Scholar 

  3. Alexander, J. W., Fischer, M. W.: Immunization against Pseudomonas in infection after thermal injury. I. infect. Dis. 130, S152-S158 (1974)

    Google Scholar 

  4. Alexander, J. W., Fischer, M. W., McMillan, B. G., Altemeier, W. A.: Prevention of invasive Pseudomonas infection in burns with a new vaccine. Arch. Surg. 99, 249–256 (1969)

    Google Scholar 

  5. Bober, L. A., Kranepool, M. J., Hollander, V. P.: Inhibitory effect of endotoxin on the growth of plasma cell tumor. Cancer Res. 36, 927–929 (1976)

    Google Scholar 

  6. Bradley, S. G., Adams, A. C., Smith, M. C.: Potentiation of the toxicity of Mithramycin by bacterial lipopolysaccharide. Antimicrob. Agents Chemother. 7, 322–327 (1975)

    Google Scholar 

  7. Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., Williamson, B.: An endotoxin-induced serum factor that causes necrosis of tumors. Proc. nat. Acad. Sci. (Wash.) 72, 3666–3670 (1975)

    Google Scholar 

  8. Clarkson, B. D., Dowling, M. D., Gee, T. S., Cunningham, I. B., Burchenal, A. H.: Treatment of acute leukemia in adults. Cancer 36, 775–795 (1975)

    CAS  PubMed  Google Scholar 

  9. Coley, W. B.: A report of recent cases of inoperable sarcomas successfully treated with mixed toxins of Erysipelas and Bacillus Prodigiosus. Surg. Gynec. Obstet. 13, 174–190 (1911)

    Google Scholar 

  10. Creech, H. J., Hamilton, M. A., Diller, I. C.: Comparative studies of the immunological, toxic and tumor necrotizing properties of polysaccharides from Serratia Marcescens cells. Canad. J. Biochem. 42, 593–603 (1964)

    Google Scholar 

  11. Diller, I. C. Degenerative changes induced in tumor cells by serratia Marcescens polysaccharide. Cancer Res. 7, 605–626 (1947)

    Google Scholar 

  12. Feller, I., Pierson, C.: Pseudomonas vaccine and hyperimmune plasma for burned patients. Arch. Surg. 97, 275–279 (1968)

    Google Scholar 

  13. Gee, T. S., Clarkson, B. D.: Pseudomonas Aeruginosa vaccine in a treatment protocol for adult patients with acute non-lymphoblastic leukemia: A preliminary report. In: Immunotherapy of cancer: Present status of trials in man (ed. W. D. Terry). New York: Raven Press (in press, 1978)

    Google Scholar 

  14. Gordon, W. C., Mandy, W. J., Prager, M. D.: Differential effect of Asparaginase of lymphocytes of populations and alleviation of the immunosuppression by Lipopolysaccharide. Cancer Immunol. Immunother. 1, 205–209 (1976)

    Google Scholar 

  15. Green, S., Carswell, E., Old, L. J., Fiore, N., Dobriansky, A., Mamaril, F., Schwartz, M. K.: Mechanisms of endotoxin-induced tumor hemorrhagic necrosis. Proc. Amer. Ass. Cancer Res. 15, 139 (1974)

    Google Scholar 

  16. Gutterman, J. U., Mavligit, G. N., Hersh, E. M.: Chemoimmunotherapy of human solid tumors. Med. Clin. N. Amer. 60, 411–461 (1976)

    Google Scholar 

  17. Haghbin, M., Armstrong, D., Murphy, M. L.: Controlled prospective trial of Pseudomonas Aeruginosa vaccine in children with acute leukemia. Cancer 32, 761–770 (1973)

    Google Scholar 

  18. Hanessian, S., Regan, W., Watson, D., Haskell, T. H.: Isolation and characterization of antigenic components of a new heptavalent pseudomonas vaccine. Nature (Lond.) New Biol. 229, 209–210 (1971)

    Google Scholar 

  19. Hartwell, J. L., Shear, M. J., Adams, R. J., Jr.: Chemical treatment of tumors. VII: Nature of hemorrhage-producing fraction from Serratia Marcescens (Bacillus Prodigiosus) culture filtrates. J. nat. Cancer Inst. 4, 107–122 (1943)

    Google Scholar 

  20. Havas, H. F., Donnelly, A. J.: Mixed bacterial toxins in the treatment of tumors. IV. Response of methylcholanthrene induced spontaneous and transplanted tumors in mice. Cancer Res. 21, 17–25 (1961)

    Google Scholar 

  21. Hersh, E. M., Gutterman, J. U., Mavligit, G., McCredie, K. B., Burgess, M. A., Mathews, A., Freireich, E. J.: Serial studies of immunocompetence of patients undergoing chemotherapy for acute leukemia. J. clin. Invest. 54, 401–408 (1974)

    Google Scholar 

  22. Horn, R. G.: Evidence for participation of granulocytes in the pathogenesis of degeneralized Schwartzman reaction: a review. J. infect. Dis. 128 (Suppl.), S134-S143 (1973)

    Google Scholar 

  23. Ikawa, M., Koepfli, J. B., Mudd, L. G., Niemann, C.: An agent from E. coli causing hemorrhage and regression of the experimental mouse tumor. I: Isolation and properties. J. nat. Cancer Inst. 13, 157–166 (1952)

    Google Scholar 

  24. Lamoureux, G., Turcotte, R., Portelance, Z.: BCG in cancer immunotherapy. New York: Grune and Stratton 1976

    Google Scholar 

  25. Landy, M., Pillemer, L.: Increased resistance to infection and accompanying alteration in properdin levels following administration of bacterial lipopolysaccharides. J. exp. Med. 104, 383–388 (1956)

    Google Scholar 

  26. Marecki, N. M., Bradley, S. G.: Enhanced toxicity for mice of combinations of bacterial endotoxin with antitumor drugs. Antimicrob. Agents Chemother. 3, 599–606 (1973)

    Google Scholar 

  27. Miller, T. R., Nicholson, J. T.: End results in reticulum cell sarcoma of bone treated by bacterial toxin therapy alone or combined with surgery and/or radiotherapy (47 cases) or concurrent infection (5 cases). Cancer 27, 524–547 (1971)

    Google Scholar 

  28. Morton, D. L.: Cancer immunotherapy: An overview. Semin. Oncol. 1, 297–310 (1974)

    Google Scholar 

  29. Nauts, H. C.: Beneficial effects of immunotherapy (bacterial toxins) on sarcoma of the soft tissues, other than lymphosarcoma. New York: Cancer Research Institute, Inc. 1975

    Google Scholar 

  30. Parr, I., Wheeler, E., Alexander, P.: Similarities of the antitumor actions of endotoxin, lipid A and double stranded RNA. Brit. J. Cancer 27, 370–389 (1973)

    Google Scholar 

  31. Peavy, D. L., Shanes, J. W., Adler, W. H., Smith, R. T.: Selective effects of bacterial endotoxins on various sub-populations of lymphoreticular cells. J. infect. Dis. 128 (Suppl.), S91-S99 (1973)

    Google Scholar 

  32. Pennington, J. E., Renault, H. Y., Wood, R. E., Robinson, R. A., Levine, A. S.: Use of a Pseudomonas Aeruginosa vaccine in patients with acute leukemia and cystic fibrosis. Amer. J. Med. 58, 629–636 (1975)

    Google Scholar 

  33. Pilch, J. H., Myers, G. H., Sparks, F. C., Golub, S. H.: Prospect for the immunotherapy of cancer. Curr. Probl. Surg. 1975

  34. Polk, H. C., Jr., Bordan, B. S., Aldrete, J. A.: Prevention of Pseudomonas respiratory infection in a surgical intensive care unit. Ann. Surg. 177, 607–615 (1973)

    Google Scholar 

  35. Ribi, E. E., Granger, D. L., Millner, K. C., Strain, S. M.: Brief communication: tumor regression caused by endotoxins and mycobacterial fractions. J. nat. Cancer Inst. 55, 1253–1257 (1975)

    Google Scholar 

  36. Rowley, D.: Rapidly induced changes in the level of non-specific immunity in laboratory animals. Griffith's J. exp. Path. 37, 223–234 (1956)

    Google Scholar 

  37. Shear, M. J., Perrault, A.: Chemical treatment of tumors IX: Reaction of mice with primary subcutaneous tumors to injection of the hemorrhage-producing bacteria Polysaccharide. J. nat. Cancer Inst. 4, 461–476 (1944)

    Google Scholar 

  38. Shear, M. J., Turner, F. C.: Chemical treatment of tumors. V: Isolation of hemorrhage-producing fraction from Serratia Marcescens (Bacillus Prodigiosus) culture filtrates. J. nat. Cancer Inst. 4, 81–97 (1943)

    Google Scholar 

  39. Smith, W. W., Alderman, I. M., Gillespie, R. E.: Hematopoietic recovery induced by bacterial endotoxin in irradiated mice. Amer. J. Physiol. 192, 549–556 (1958)

    Google Scholar 

  40. Strausser, H. R., Bober, L. A.: Inhibition of tumor growth and survival of aged mice inoculated with Maloney tumor transplants and treated with endotoxin. Cancer Res. 32, 2156–2159 (1972)

    Google Scholar 

  41. Whitby, J. L., Rolley, D.: The role of macrophages in the elimination of bacteria from the mouse peritoneum. Brit. J. exp. Path. 40, 358–370 (1959)

    Google Scholar 

  42. Young, L. S., Meyer, R. D., Armstrong, D.: Pseudomonas Aeruginosa vaccine in cancer patients. Ann. intern. Med. 79, 518–527 (1973)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Medicine and Dept. of Developmental Therapeutics, University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, 6723, Bertner Avenue, 77030, Houston, Texas, USA

    G. N. Hortobagyi, R. D. Snyder, S. P. Richman & E. M. Hersh

  2. Recipient of a Research Career Development Award (Ac-71001-03) from National Cancer Institute, 20014, Bethesda, Maryland, USA

    J. U. Gutterman (Recipient), R. D. Snyder, S. P. Richman & E. M. Hersh

Authors
  1. G. N. Hortobagyi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. U. Gutterman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. D. Snyder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. P. Richman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. M. Hersh
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hortobagyi, G.N., Gutterman, J.U., Snyder, R.D. et al. Pseudomonas vaccine: A phase I evaluation for cancer research. Cancer Immunol Immunother 4, 201–207 (1978). https://doi.org/10.1007/BF00204741

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00204741

Keywords

Search

Navigation